Literature DB >> 21128937

Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease.

Anna Witasp1, Juan J Carrero, Folke Hammarqvist, Abdul R Qureshi, Olof Heimbürger, Martin Schalling, Bengt Lindholm, Louise Nordfors, Peter Stenvinkel.   

Abstract

BACKGROUND: Premature vascular calcification (or rather ossification) significantly contributes to morbidity and mortality in patients with chronic kidney disease stage 5 (CKD-5) and is linked to dysregulation of bone remodelling proteins. Recent evidence of a cross-talk between bone and fat tissue urged us to investigate whether the calcification/ossification-associated factors osteoprotegerin (OPG) and alpha-2-HS-glycoprotein (AHSG) are expressed in human uremic subcutaneous adipose tissue (SAT) and if the expression differs from nonuremic SAT.
MATERIALS AND METHODS: Abdominal SAT biopsies were obtained from 38 patients with CKD-5 [16 women, 58 (22-73) years old] during the surgical insertion of a peritoneal dialysis catheter and 20 controls [11 females, 56 (40-77) years old] undergoing elective hernia repair or laparoscopic cholecystectomy. Real-time polymerase chain reaction (PCR) quantifications were performed followed by immunohistochemical staining and serum protein concentration measurements. Relative mRNA expression and protein concentrations were evaluated together with clinical parameters. An additional 59 patients with CKD-5 were included for replication of statistical analyses.
RESULTS: OPG but not AHSG mRNAs were detected in SAT, which were also positively immunolabelled for OPG. OPG mRNA levels were reduced (P = ·0001) and serum OPG concentrations were elevated (P < 0·0001), both about twofold, in patients compared to controls. Circulating OPG increased in proportion to BMI.
CONCLUSIONS: Human SAT expresses OPG but not AHSG, and OPG expression is reduced in patients with CKD-5 when compared to controls, despite increased circulating protein levels.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21128937     DOI: 10.1111/j.1365-2362.2010.02432.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

1.  Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome.

Authors:  D Glintborg; A P Hermann; L M Rasmussen; M Andersen
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

Review 2.  Protein Nutrition and Malnutrition in CKD and ESRD.

Authors:  Yan Zha; Qi Qian
Journal:  Nutrients       Date:  2017-02-27       Impact factor: 5.717

3.  Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure.

Authors:  Ying-Hsien Chen; Yen-Wen Wu; Wei-Shiung Yang; Shoei-Shen Wang; Chi-Ming Lee; Nai-Kuan Chou; Ron-Bin Hsu; Yen-Hung Lin; Mao-Shin Lin; Yi-Lwun Ho; Ming-Fong Chen
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

4.  The relationship between malnutrition risk and inflammatory biomarkers in outpatient geriatric population.

Authors:  Paulina Fatyga; Agnieszka Pac; Małgorzata Fedyk-Łukasik; Tomasz Grodzicki; Anna Skalska
Journal:  Eur Geriatr Med       Date:  2020-03-06       Impact factor: 1.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.